Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:25 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions: 13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 44
States / cities: Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more

Conditions: Influenza
Interventions: mRNA-1018-H5, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 4,050 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: San Bernardino, California • Savannah, Georgia • Meridian, Idaho + 7 more

Conditions: Childhood Influenza Vaccination, School-located Influenza Vaccination
Interventions: School-located Influenza Vaccination Clinic; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 4 Years to 19 Years
Enrollment: 20,461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza
Interventions: Fluzone® Quadrivalent Influenza Vaccine, No Preservative; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 8 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: H1N1 Influenza Virus
Interventions: H1N1 vaccine high dose, H1N1 vaccine low dose; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 7
States / cities: Atlanta, Georgia • St Louis, Missouri • Winston-Salem, North Carolina + 4 more

Conditions: Influenza Immunization
Interventions: Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 3 Years to 8 Years
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 14 more

Conditions: Influenza
Interventions: FluMist; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 3,022 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: Influenza
Interventions: Cold-adapted live attenuated influenza virus vaccine, trivalent, Placebo, Trivalent inactivated influenza vaccine; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 2,349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 6
States / cities: Ann Arbor, Michigan • Kalamazoo, Michigan • Livonia, Michigan + 2 more

Conditions: Influenza, Human, COVID-19
Interventions: Comirnaty, Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,442,996 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Vaccine Hesitancy
Interventions: Text messaging; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 6 Months and older
Enrollment: 228,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 3 Years to 22 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: East Setauket, New York

Conditions: Flu
Interventions: Dose given at Day 0; Biological
Lead sponsor: Medicago; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Influenza, COVID-19
Interventions: Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine); Biological
Lead sponsor: Duke University; Other
Eligibility: 6 Years to 64 Years
Enrollment: 455 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 8
States / cities: Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more

Conditions: Influenza, Healthy
Interventions: Trivalent Influenza Vaccine, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Stockbridge, Georgia • Portland, Oregon

Conditions: Influenza Disease; Flu
Interventions: Influenza Virus Vaccine; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 613 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Bardstown, Kentucky • Pittsburgh, Pennsylvania • Salt Lake City, Utah

Conditions: Grippe, Influenza, Vaccines
Interventions: pdmFlu vaccine, Placebo, Licensed influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: New Haven, Connecticut • Hollywood, Florida • New York, New York

Conditions: Influenza A Virus Infection
Interventions: High-titer anti-influenza plasma, Low-titer anti-influenza plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Weeks and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 30
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 23 more

Conditions: Anosmia, Asymptomatic COVID-19, COVID-19 Respiratory Infection, Influenza, Healthy, PASC Post Acute Sequelae of COVID 19
Interventions: AROMHA Longitudinal Smell Test; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza, Influenza, Human, Influenza -Like Illness
Interventions: Oseltamivir, Baloxavir; Drug
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza
Interventions: Influenza Vaccination; Biological
Lead sponsor: Protein Sciences Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 870 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Baltimore, Maryland • Rochester, Minnesota • Shrewsbury, New Jersey + 3 more

Conditions: Influenza
Interventions: Trivalent Subviron Influenza vaccine (Fluzone); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza Immunization
Interventions: Quadrivalent Influenza mRNA Vaccine MRT5413, Quadrivalent Recombinant Influenza Vaccine, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 28
States / cities: Chula Vista, California • Gardena, California • Long Beach, California + 24 more

Conditions: Influenza, Pandemic
Interventions: BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM; Biological
Lead sponsor: BlueWillow Biologics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults

Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Safety and Efficacy of an H1N1 Influenza Vaccine in People With Asthma

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

FLU-VACS Comparative Study in Adults

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Precision Vaccine Promotion in Underserved Populations

Flu Vaccine Response in Patients on Biologic Therapies

Safety, Tolerability and Immunogenicity of a Plant-Made H1 VLP Influenza Vaccine in Adults

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults

Study of the Safety and Immunogenicity of an Influenza Vaccine Administered to Healthy Adults

A Study to Learn How Safe, Tolerable and Capable of Producing an Immune Response is, a Modified RNA Vaccine Against Pandemic Influenza

Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A

Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza Vaccine in Pediatric Transplant Subjects

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Pandemic Flu Vaccine in Healthy Adults